New Ventures & Transactions Lead, Cardiovascular & Metabolic Diseases
Rosemary is the New Ventures and Transactions Lead for Cardiovascular and Metabolic (CVM) Diseases at Johnson & Johnson Innovation, London. In this role, Rosemary is responsible for sourcing and executing on the delivery of transformational, innovative opportunities for healthcare in the Cardiovascular and Metabolic space across EMEA.
Before this role, Rosemary was a Healthcare Solutions Lead for Johnson & Johnson Health & Wellness Solutions, based in the UK. In this position, she worked with the Janssen UK business and EMEA strategy organisation to launch an innovative digital platform in pilot centres in the UK, and was also responsible for sourcing potential partnerships to complement the team’s digital solution strategy. Previously, Rosemary was a Director on the Medical Devices Equity Research team at Oppenheimer & Co. in New York City, where she supported Oppenheimer’s research platform for device companies operating across various therapy areas, including cardiac rhythm management, orthopaedics, diabetes, and heart failure. Rosemary started her career as an investment banking analyst at Merrill Lynch.
Rosemary holds an MBA from London Business School and a BA in Economics and Psychology from the University of Virginia.